medigraphic.com
ISSN 1560-4381 (Impreso)

2022, Número 1

<< Anterior Siguiente >>

Correo Científico Médico 2022; 26 (1)


Factor estimulante de colonia de granulocitos en la enfermedad cerebrovascular: Revisión

Méndez HCR, Wainshtok TDM, López RI

Idioma: Español
Referencias bibliográficas: 33
Paginas: 184-196
Archivo PDF: 379.29 Kb.


RESUMEN

El factor estimulante de colonias de granulocitos (FEC-G) fomenta la maduración y diferenciación de los progenitores granulocíticos en la médula ósea. Su aplicación genera la liberación de un número importante de células madre hematopoyéticas que tienen la capacidad de diferenciarse en células de otros tejidos como el nervioso, de ahí que se haya propuesto como un posible candidato terapéutico en las enfermedades cerebrovasculares. Según los resultados de los estudios preclínicos el FEC-G se investiga como opción de tratamiento específico de la enfermedad cerebrovascular; no obstante, se requieren estudios clínicos más amplios y por un período mayor de tiempo.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Noya Chaveco ME, Moya González NL. Enfermedades cerebrovasculares. En: Roca Goderich. Temas de Medicina Interna: T.II. 5ta ed. La Habana: Ciencias Médicas; 2017.[citado 25/07/2020].Disponible en:http://www.bvscuba.sld.cu/libro/roca-goderich-temas-de-medicina-interna-tomo-2-5ta-ed/

  2. Chamorro Sánchez Á. Accidentes vasculares cerebrales. En: Rozman C, Cardellach López F, Nicolás JM, Cervera R. Farreras-Rozman. Medicina Interna. V.II. 19a ed. Barcelona, España: Elsevier; 2020. p. 1375-88.

  3. Smith WS, Johnston SC, Hemphill JC. Enfermedades cerebrovasculares. En: Fauci AS, Kasper DL, Longo DL, Braunwald E, Hauser SL, Jameson JL, et al. Harrison. Principios de Medicina Interna. V.II. 20a ed. Ciudad de México: McGraw-Hill Education; 2018. p. 3068-3079.

  4. Krag AE, Ankerlund Blauenfeldt A. Fibrinolysis and Remote Ischemic Conditioning: Mechanisms and Treatment Perspectives in Stroke. Semin Thromb Hemost.2021[citado 25/01/2021];47(05):610-620. Disponible en:https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0041-1725095

  5. Llibre JJ, Valhuerdi A, Fernández O, Llibre JC, Porto R, López AM, Marcheco B, et al. Prevalence of stroke and associated risk factors in older adults in Havana City and Matanzas Provinces, Cuba (10/66 population-based study). MEDICC Rev. 2010[citado 25/07/2020];12(3):20-26. Disponible en:https://mediccreview.org/wp-content/uploads/2018/03/mr_153.pdf

  6. Bembibre Taboada R, Alfonso Falcón D, Jova Dueñas JH, Pérez Ramos T. Guía de práctica clínica para el tratamiento de la enfermedad cerebrovascular. Medisur.2009 [citado 04/12/2020];7(1). Disponible en: http://medisur.sld.cu/index.php/medisur/article/view/706

  7. Liska MG, Dela Peña I. Granulocyte-colony stimulating factor and umbilical cord blood cell transplantation: synergistic therapies for the treatment of traumatic brain injury. Brain Circ 2017 [citado 28/08/2020];3(3):143-151. Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057694/

  8. Wei X, Xu Y, Jin Y, Feng H, Xiao Y, Dong S. Granulocyte colony-stimulating factor attenuates blood-brain barrier damage and improves cognitive function in spontaneously hypertensive rats. CNS Neurol Disord Drug Targets.2017 [citado 15/02/2020];16(7):781-788. Disponible en: http://www.eurekaselect.com/article/81605

  9. Shen LH, Chen J, Shen HC, Ye M, Liu XF, Ding WS, et al. Possible mechanism of therapeutic effect of 3-Methyl-1-phenyl-2-pyrazolin-5-one and bone marrow stromal cells combination treatment in rat ischemic stroke model. Chin Med J (Engl). 2016 [citado 25/2020];129(12):1471-1476. Disponible en: https://medcentral.net/doi/full/10.4103/0366-6999.183418

  10. Farokhnia M, Berger AL, Karoly HC, Hwa LS, Varodayan FP. The promise of neuroimmune targets for treating drug addiction and other psychiatric disorders: granulocyte-colony stimulating factor exemplification. Front Psychiatry.2020[citado 15/11/2020];11:220. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7090216/

  11. Lu CZ, Xiao BG. Neuroprotection of G-CSF in cerebral ischemia. Front Biosci. 2007 [citado 15/11/2020];12 (8) :2869-2875. Disponible en:https://www.fbscience.com/Landmark/articles/10.2741/2278

  12. Zhao LR, Piao CS, Murikinati SR, Gonzalez Toledo ME. The role of stem cell factor and granulocyte-colony stimulating factor in treatment of stroke. Recent Pat CNS Drug Discov. 2013[citado 15/08/2020];8(1):2-12. Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3740536/

  13. Sanchez Ramos J, Song S, Sava V, Catlow B, Lin X, Mori T, et al. Granulocyte colony stimulating factor decreases brain amyloid burden and reverses cognitive impairment in Alzheimer's mice. Neuroscience.2009 [citado 25/08/2021];163(1):55-72. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5966834/

  14. Huang X, Liu Y, Bai S, Peng L, Zhang B, Lu H. Granulocyte colony stimulating factor therapy for stroke: A pairwise meta-analysis of randomized controlled trial. PLoS One.2017[citado 15/12/ 2020];12(4):e0175774. Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391086/

  15. Salamone P, Fuda G, Casale F, Marrali G, Lunetta C, Caponnetto C, et al. G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial). BMJ Open. 2020[citado 15/08/2020];10(3):034049. Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202695/

  16. England TJ, Abaei M, Auer DP, Lowe J, Jones DR, Sare G, et al. Granulocyte-colony stimulating factor for mobilizing bone marrow stem cells in subacute stroke: the stem cell trial of recovery enhancement after stroke 2 randomized controlled trial. Stroke.2012 [citado 15/05/2020];43(2):405-411. Disponible en:https://www.ahajournals.org/doi/full/10.1161/STROKEAHA.111.636449

  17. Céspedes Quevedo MC, Segura López D, Martínez Rodríguez E, Cobas Ramos Z, Bronfield Caballero D. Factor estimulante de colonias de granulocitos en pacientes con cáncer. Medisan.2013 [citado 24/04/2020]; 17(1):45-53. Disponible en:http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1029-30192013000100007

  18. England T, Sprigg N, Alasheev A, Belkin A, Kumar A , Prasad K, et al. Granulocyte-colony stimulating factor (G-CSF) for stroke: an individual patient data meta-analysis. Sci Rep.2016 [citado 25/07/2020];6,36567. Disponible en: https://www.nature.com/articles/srep36567

  19. Mizuma A, Yamashita T, Kono S, Nakayama T, Baba Y, Itoh S, et al. Phase II trial of intravenous low-dose granulocyte colony-stimulating factor in acute ischemic stroke. J Stroke Cerebrovasc Dis.2016[citado 25/06/15];25(6);1451-1457. Disponible en:https://www.sciencedirect.com/science/article/abs/pii/S1052305716000355

  20. Hu Z, Chen Z, Wang Y, Jiang J, Tse G, Xu W, et al. Effects of granulocyte colony-stimulating factor on rabbit carotid and porcine heart models of chronic obliterative arterial disease. Mol Med Rep.2019 [citado 28/02/2021];19(6):4569-4578. Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522810/

  21. Ding J, Yu JZ, Li QY, Wang X, Lu CZ, Xiao BG. Rho kinase inhibitor fasudil induces neuroprotection and neurogenesis partially through astrocyte-derived G-CSF. Brain Behav Immun.2009[citado 29/07/2020];23(8):1083-1088. Disponible en:https://www.sciencedirect.com/science/article/abs/pii/S0889159109001160

  22. Rafik Patel AM, Apaijai N, Chattipakorn N, Chattipakorn S. The protective and reparative role of colony stimulating factors in the brain with cerebral ischemia/reperfusion injury. Neuroendocrinology. 2021[citado 25/08/202];111(11):1029-1065. Disponible en:https://www.karger.com/Article/FullText/512367

  23. Wang W, Chen L, Ruan L, Jin K, Zhuge Q. Mobilization and homing of bone marrow stem cells after stroke.En: Jin K, Ji X, Zhuge Q. Bone marrow stem cell therapy for stroke. Singapore: Springer; 2017.p.55-79.

  24. Duelsner A, Gatzke N, Glaser J, Hillmeister P, Li M, Lee EJ, et al. Granulocyte colony-stimulating factor improves cerebrovascular reserve capacity by enhancing collateral growth in the circle of Willis. Cerebrovasc Dis. 2014 [citado 25/07/2020];33(5):419-429. Disponible en:https://www.proquest.com/openview/65ca4821f46030502686ac3150d1c0c7/1?pq-origsite=gscholar&cbl=34028

  25. Paszko Patej G, Sienkiewicz D, Okurowska Zawada B, Kułak W, Granulocyte colony-stimulating factor potential use in the treatment of children with cerebral palsy. Prog Health Sci.2017[citado 25/01/2020];7(1)187-192. Disponible en:https://www.umb.edu.pl/photo/pliki/progress-file/phs/phs_2017_1/187-192_paszko_0.pdf

  26. Nguyen H, Aum D, Mashkouri S, Rao G, Vega Gonzales Portillo JD, Reyes S, et al. Growth factor therapy sequesters inflammation in affording neuroprotection in cerebrovascular diseases. Expert Rev Neurother.2016 [citado 25/04/2020];16(8):915-926. Disponible en: https://www.tandfonline.com/doi/full/10.1080/14737175.2016.1184086

  27. Sprigg N, O'Connor R, Woodhouse L, Krishnan K, England TJ, Connell LA, et al. Granulocyte colony stimulating factor and physiotherapy after stroke: results of a feasibility randomized controlled trial: stem cell trial of recovery enhancement after Stroke-3 (STEMS-3 ISRCTN16714730). PLoS One.2016 [citado 25/07/2020];11(9):0161359. Disponible en: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0161359

  28. Campos Mojena R, Marín Prida J, Piniella Matamoros B, Pardo Andreu GL, Pentón Rol G. Isquemia cerebral: mecanismos fisiopatológicos y oportunidades terapéuticas. Rev Cienc Farm Aliment.2016 [citado 25/07/2021];2(1). Disponible en:http://www.rcfa.uh.cu/index.php/RCFA/article/view/58/90

  29. Peña ID, Borlongan C, Shen G, Davis W. Strategies to extend thrombolytic time window for ischemic stroke treatment: an unmet clinical need. J Stroke. 2017 [Consulted 04/05/2021];19(1):50-60. Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5307939/

  30. Hu X, De Silva TM, Chen J, Faraci FM. Cerebral vascular disease and neurovascular injury in ischemic stroke. Circ Res. 2017 [citado 29/05/2020];120(3):449-471. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5313039/

  31. Ping S, Qiu X, Gonzalez Toledo ME, Liu X, Zhao LR. Stem cell factor in combination with granulocyte colony-stimulating factor reduces cerebral capillary thrombosis in a mouse model of CADASIL. Cell Transplant.2018 [citado 28/07/2020];27(4):637-647. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6041883/

  32. Guan ZF, Tao YH, Zhang XM, Guo QL, Liu YC, Zhang Y, et al. G-CSF and cognitive dysfunction in elderly diabetic mice with cerebral small vessel disease: preventive intervention effects and underlying mechanisms. CNS Neurosci Ther.2017 [citado 25/07/2020];23(6):462-474. Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492719/

  33. Guo X, Liu Y, Morgan D, Zhao LR. Reparative effects of stem cell factor and granulocyte colony-stimulating factor in aged APP/PS1 mice. Aging Dis.2020 [citado 27/01/2021];11(6):1423-1443. Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673847/




2020     |     www.medigraphic.com